Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1
Annals of Internal Medicine · 2026-02 · 179 (2) · 168-176
DOI: 10.7326/annals-25-01939 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2026-02. Verfasst von Amy E Colson und 22 weiteren Autor:innen. Beteiligte Einrichtung: Community Resource Initiative, Boston, and Cambridge Health Alliance, Cambridge, Massachusetts (A.E.C.). Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Emtricitabine, Anti-HIV Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Once-weekly oral islatravir plus lenacapavir (ISL+LEN) has the potential to address adherence challenges with daily HIV-1 treatment. OBJECTIVE: To evaluate efficacy and safety of once-weekly ISL+LEN. DESIGN: Phase 2, randomized, open-label, active-controlled study. (ClinialTrials.gov: NCT05052996). SETTING: 44 U.S. sites. PARTICIPANTS: Adults with HIV-1 RNA viral load of less than 50 copies/mL receiving daily bictegravir, emtricitabine, and tenofovir alafenamide combination (B/F/TAF) for 24 weeks or more. INTERVENTION: Once-weekly oral ISL, 2 mg, plus LEN, 300 mg, or daily oral B/F/TAF. MEASUREMENTS: Proportion with HIV-1 RNA viral load of 50 copies/mL or more at week 24 (primary end point; U.S. Food and Drug Administration Snapshot Algorithm). Secondary end points: proportion of participants with HIV-1 RNA viral load of 50 copies/mL or more (weeks 12 and 48) and HIV-1 RNA viral load of less than 50 copies/mL (weeks 12, 24. and 48), safety, and CD4+ T-cell and lymphocyte count changes (weeks 12, 24, and 48). RESULTS: A total of 104 participants were randomly assigned and treated (n = 52 per group). At week 24, one ISL+LEN participant and no B/F/TAF participants had HIV-1 RNA viral load of 50 copies/mL or more (difference, 1.9% [95% CI, -5.2% to 10.5%]); 94.2% of participants in both groups had HIV-1 RNA viral load of less than 50 copies/mL (difference, 0% [CI, -10.9% to 10.9%]). At week 48, 94.2% and 92.3% of ISL+LEN and B/F/TAF participants, respectively, had HIV-1 RNA viral load of less than 50 copies/mL (difference, 1.9% [CI, -9.3% to 13.6%]); no participant had HIV-1 RNA viral load of 50 copies/mL or more. Two ISL+LEN participants discontinued treatment (before week 24) due to adverse events (AEs) unrelated to the study drug. No AEs that were grade 3 or greater or serious were related to treatment in either group. Changes in CD4+ T-cell and lymphocyte counts from baseline to week 48 were similar between groups, with no discontinuations of study drug treatment due to decreased CD4+ T cells or lymphocytes. LIMITATION: Open-label, modest sample size, and only U.S.-based participants. CONCLUSION: Once-weekly oral ISL+LEN maintained high rates of virologic suppression through week 48 and was not associated with any treatment-related grade 3 or greater or serious AEs. PRIMARY FUNDING SOURCE: Gilead Sciences, Inc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Community Resource Initiative, Boston, and Cambridge Health Alliance, Cambridge, Massachusetts (A.E.C.).
- The Crofoot Research Center, Houston, Texas (G.E.C.).
- Ruane Clinical Research, Los Angeles, California (P.J.R.).
- Midway Immunology & Research Center, Fort Pierce, Florida (M.N.R.).
- Metro Infectious Disease Consultants, Decatur, Georgia (A.W.D.).
- IDCare, Hillsborough, New Jersey (R.G.N.).
ORCID-Profile: Alexandra W Dretler, Ronald G Nahass, Shauna Applin, Cynthia Brinson, Dushyantha Jayaweera, Kimberly A Workowski, Stephanie Klopfer, Sharline Madera, Joseph J Eron
Zitieren
APA
Colson, A. E., Crofoot, G. E., Ruane, P. J., Ramgopal, M. N., Dretler, A. W., Nahass, R. G., Sinclair, G. I., Berhe, M., Roberts, A., Applin, S., Brinson, C., Jayaweera, D., Workowski, K. A., Shihadeh, F., Liu, S. Y., Klopfer, S., Llamoso, C., Madera, S., Dvory-Sobol, H., …, & Eron, J. J. (2026). Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1. Annals of Internal Medicine, 179(2), 168-176. https://doi.org/10.7326/annals-25-01939
Vancouver
Colson AE, Crofoot GE, Ruane PJ, Ramgopal MN, Dretler AW, Nahass RG, et al. Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1. Annals of Internal Medicine. 2026;179(2):168-176. doi:10.7326/annals-25-01939
BibTeX
@article{Colson2026,
author = {Colson, Amy E and Crofoot, Gordon E and Ruane, Peter J and Ramgopal, Moti N and Dretler, Alexandra W and Nahass, Ronald G and Sinclair, Gary I and Berhe, Mezgebe and Roberts, Afsoon and Applin, Shauna and Brinson, Cynthia and Jayaweera, Dushyantha and Workowski, Kimberly A and Shihadeh, Fadi and Liu, Shan-Yu and Klopfer, Stephanie and Llamoso, Cyril and Madera, Sharline and Dvory-Sobol, Hadas and Rhee, Martin S and Rhee, Elizabeth G and Baeten, Jared M and Eron, Joseph J},
title = {Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1},
journal = {Annals of Internal Medicine},
year = {2026},
volume = {179},
number = {2},
pages = {168--176},
doi = {10.7326/annals-25-01939}
}
EUVIMED